Abstract
BackgroundRemission is only achieved in part of rheumatoid arthritis (RA) patients treated with synthetic disease modifying anti-rheumatic drugs, sDMARDs. The increasing number of available biologic DMARDs (bDMARDs) challenges treatment decision...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
